Novavax (NVAX) Competitors $7.84 +0.21 (+2.75%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.88 +0.04 (+0.57%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVAX vs. MRNA, OCGN, VXRT, JNJ, PFE, ALKS, LGND, FOLD, BCRX, and CLDXShould you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Moderna (MRNA), Ocugen (OCGN), Vaxart (VXRT), Johnson & Johnson (JNJ), Pfizer (PFE), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), and Celldex Therapeutics (CLDX). These companies are all part of the "medical" sector. Novavax vs. Its Competitors Moderna Ocugen Vaxart Johnson & Johnson Pfizer Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation. Which has better valuation & earnings, MRNA or NVAX? Novavax has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.26-$3.56B-$7.53-3.60Novavax$1.08B1.18-$187.50M$2.283.44 Do analysts prefer MRNA or NVAX? Moderna presently has a consensus price target of $42.88, suggesting a potential upside of 58.12%. Novavax has a consensus price target of $15.57, suggesting a potential upside of 98.62%. Given Novavax's stronger consensus rating and higher possible upside, analysts plainly believe Novavax is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Novavax 3 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13 Which has more volatility and risk, MRNA or NVAX? Moderna has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Novavax has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Does the media favor MRNA or NVAX? In the previous week, Moderna had 2 more articles in the media than Novavax. MarketBeat recorded 22 mentions for Moderna and 20 mentions for Novavax. Moderna's average media sentiment score of 0.73 beat Novavax's score of 0.44 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 4 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Is MRNA or NVAX more profitable? Novavax has a net margin of 39.20% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Novavax's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% Novavax 39.20%-142.33%28.65% Do institutionals and insiders have more ownership in MRNA or NVAX? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 11.0% of Moderna shares are owned by insiders. Comparatively, 1.0% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryNovavax beats Moderna on 9 of the 17 factors compared between the two stocks. Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVAX vs. The Competition Export to ExcelMetricNovavaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27B$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio3.4421.0031.3626.05Price / Sales1.18209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book34.098.129.536.60Net Income-$187.50M-$54.72M$3.26B$265.65M7 Day Performance-18.16%2.62%2.14%2.00%1 Month Performance2.62%3.25%3.22%0.46%1 Year Performance-34.61%10.82%30.18%18.88% Novavax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVAXNovavax4.6172 of 5 stars$7.84+2.8%$15.57+98.6%-34.6%$1.27B$1.08B3.441,990News CoverageAnalyst ForecastMRNAModerna4.5074 of 5 stars$28.08+0.2%$43.59+55.3%-67.1%$10.92B$3.24B-3.735,800News CoverageAnalyst ForecastOCGNOcugen1.0673 of 5 stars$1.04-1.0%$6.00+476.9%-22.3%$303.99M$4.05M-5.2080VXRTVaxart2.687 of 5 stars$0.36-0.4%$2.00+448.5%-63.4%$83.47M$47.40M-1.35120News CoverageGap DownJNJJohnson & Johnson4.8739 of 5 stars$176.26-0.2%$174.50-1.0%+9.1%$424.49B$90.63B18.85138,100Trending NewsAnalyst ForecastPFEPfizer4.6738 of 5 stars$25.07-0.3%$28.12+12.2%-10.6%$142.54B$63.63B13.3481,000Trending NewsALKSAlkermes4.741 of 5 stars$28.12-3.2%$41.08+46.1%+6.4%$4.64B$1.56B13.521,800Trending NewsAnalyst RevisionLGNDLigand Pharmaceuticals4.1149 of 5 stars$153.26+1.4%$157.00+2.4%+53.2%$3.00B$187.58M-38.3280News CoveragePositive NewsShort Interest ↓FOLDAmicus Therapeutics4.353 of 5 stars$7.41+0.1%$16.22+118.9%-35.3%$2.28B$571.16M-61.74480News CoveragePositive NewsBCRXBioCryst Pharmaceuticals4.2021 of 5 stars$8.38+0.1%$16.70+99.3%+5.7%$1.76B$450.71M-46.55530Positive NewsCLDXCelldex Therapeutics1.6032 of 5 stars$24.48-4.0%$51.75+111.4%-39.6%$1.63B$7.02M-8.13150News CoverageAnalyst Forecast Related Companies and Tools Related Companies Moderna Alternatives Ocugen Alternatives Vaxart Alternatives Johnson & Johnson Alternatives Pfizer Alternatives Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVAX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access